Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Coupling between beta band and high frequency oscillations as a clinically useful biomarker for DBS

M. Bočková, M. Lamoš, J. Chrastina, P. Daniel, S. Kupcová, I. Říha, L. Šmahovská, M. Baláž, I. Rektor

. 2024 ; 10 (1) : 40. [pub] 20240221

Status not-indexed Language English Country United States

Document type Journal Article

Grant support
21-25953S Grantová Agentura České Republiky (Grant Agency of the Czech Republic)
21-25953S Grantová Agentura České Republiky (Grant Agency of the Czech Republic)
21-25953S Grantová Agentura České Republiky (Grant Agency of the Czech Republic)
21-25953S Grantová Agentura České Republiky (Grant Agency of the Czech Republic)

Beta hypersynchrony was recently introduced into clinical practice in Parkinson's disease (PD) to identify the best stimulation contacts and for adaptive deep brain stimulation (aDBS) sensing. However, many other oscillopathies accompany the disease, and beta power sensing may not be optimal for all patients. The aim of this work was to study the potential clinical usefulness of beta power phase-amplitude coupling (PAC) with high frequency oscillations (HFOs). Subthalamic nucleus (STN) local field potentials (LFPs) from externalized DBS electrodes were recorded and analyzed in PD patients (n = 19). Beta power and HFOs were evaluated in a resting-state condition; PAC was then studied and compared with the electrode contact positions, structural connectivity, and medication state. Beta-HFO PAC (mainly in the 200-500 Hz range) was observed in all subjects. PAC was detectable more specifically in the motor part of the STN compared to beta power and HFOs. Moreover, the presence of PAC better corresponds to the stimulation setup based on the clinical effect. PAC is also sensitive to the laterality of symptoms and dopaminergic therapy, where the greater PAC cluster reflects the more affected side and medication "off" state. Coupling between beta power and HFOs is known to be a correlate of the PD "off" state. Beta-HFO PAC seems to be more sensitive than beta power itself and could be more helpful in the selection of the best clinical stimulation contact and probably also as a potential future input signal for aDBS.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24005742
003      
CZ-PrNML
005      
20240412131031.0
007      
ta
008      
240405s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41531-024-00656-8 $2 doi
035    __
$a (PubMed)38383550
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Bočková, Martina $u Brain and Mind Research Program, Central European Institute of Technology, Masaryk University, Brno, Czech Republic $u First Department of Neurology, Masaryk University School of Medicine, St. Anne's Hospital, Brno, Czech Republic $1 https://orcid.org/0000000326919122
245    10
$a Coupling between beta band and high frequency oscillations as a clinically useful biomarker for DBS / $c M. Bočková, M. Lamoš, J. Chrastina, P. Daniel, S. Kupcová, I. Říha, L. Šmahovská, M. Baláž, I. Rektor
520    9_
$a Beta hypersynchrony was recently introduced into clinical practice in Parkinson's disease (PD) to identify the best stimulation contacts and for adaptive deep brain stimulation (aDBS) sensing. However, many other oscillopathies accompany the disease, and beta power sensing may not be optimal for all patients. The aim of this work was to study the potential clinical usefulness of beta power phase-amplitude coupling (PAC) with high frequency oscillations (HFOs). Subthalamic nucleus (STN) local field potentials (LFPs) from externalized DBS electrodes were recorded and analyzed in PD patients (n = 19). Beta power and HFOs were evaluated in a resting-state condition; PAC was then studied and compared with the electrode contact positions, structural connectivity, and medication state. Beta-HFO PAC (mainly in the 200-500 Hz range) was observed in all subjects. PAC was detectable more specifically in the motor part of the STN compared to beta power and HFOs. Moreover, the presence of PAC better corresponds to the stimulation setup based on the clinical effect. PAC is also sensitive to the laterality of symptoms and dopaminergic therapy, where the greater PAC cluster reflects the more affected side and medication "off" state. Coupling between beta power and HFOs is known to be a correlate of the PD "off" state. Beta-HFO PAC seems to be more sensitive than beta power itself and could be more helpful in the selection of the best clinical stimulation contact and probably also as a potential future input signal for aDBS.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Lamoš, Martin $u Brain and Mind Research Program, Central European Institute of Technology, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000312764342
700    1_
$a Chrastina, Jan $u Department of Neurosurgery, Masaryk University School of Medicine, St. Anne's Hospital, Brno, Czech Republic
700    1_
$a Daniel, Pavel $u Brain and Mind Research Program, Central European Institute of Technology, Masaryk University, Brno, Czech Republic $u First Department of Neurology, Masaryk University School of Medicine, St. Anne's Hospital, Brno, Czech Republic
700    1_
$a Kupcová, Silvia $u Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Říha, Ivo $u Department of Neurosurgery, Masaryk University School of Medicine, St. Anne's Hospital, Brno, Czech Republic
700    1_
$a Šmahovská, Lucia $u First Department of Neurology, Masaryk University School of Medicine, St. Anne's Hospital, Brno, Czech Republic $u Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Baláž, Marek $u Brain and Mind Research Program, Central European Institute of Technology, Masaryk University, Brno, Czech Republic $u First Department of Neurology, Masaryk University School of Medicine, St. Anne's Hospital, Brno, Czech Republic
700    1_
$a Rektor, Ivan $u Brain and Mind Research Program, Central European Institute of Technology, Masaryk University, Brno, Czech Republic. ivan.rektor@fnusa.cz $u First Department of Neurology, Masaryk University School of Medicine, St. Anne's Hospital, Brno, Czech Republic. ivan.rektor@fnusa.cz $1 https://orcid.org/0000000296357404 $7 nlk19990073773
773    0_
$w MED00208625 $t NPJ Parkinson's disease $x 2373-8057 $g Roč. 10, č. 1 (2024), s. 40
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38383550 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240405 $b ABA008
991    __
$a 20240412131024 $b ABA008
999    __
$a ok $b bmc $g 2076009 $s 1215504
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2024 $b 10 $c 1 $d 40 $e 20240221 $i 2373-8057 $m NPJ Parkinson's disease $n NPJ Parkinsons Dis $x MED00208625
GRA    __
$a 21-25953S $p Grantová Agentura České Republiky (Grant Agency of the Czech Republic)
GRA    __
$a 21-25953S $p Grantová Agentura České Republiky (Grant Agency of the Czech Republic)
GRA    __
$a 21-25953S $p Grantová Agentura České Republiky (Grant Agency of the Czech Republic)
GRA    __
$a 21-25953S $p Grantová Agentura České Republiky (Grant Agency of the Czech Republic)
LZP    __
$a Pubmed-20240405

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...